Key points are not available for this paper at this time.
Regulators and industry continue to prioritize survival-based end points rather than patient-experience end points in cancer-drug development. Yet as patients live longer with cancer, they must increasingly choose among agents with varying efficacy–toxicity balances.
Ethan Basch (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: